Stromal tumour-infiltrating lymphocytes (sTIL) give a valuable insight into the anti-tumour response and have been correlated with prognosis in the more aggressive and proliferative triple negative (TN) and human epidermal growth factor receptor 2 (HER2+) subtypes of breast cancer [6]. Here, ERBB2 is linked to breast cancer.